Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:11:17 2025-07-15 EDT			5-day change	1st Jan Change
83.54 ^USD	-0.15%		+3.03%	-15.73%

07:53am	Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million	RE
07-14	Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill	CI

Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial

Published on 2025-06-10 at 07:32, updated on 2025-06-10 at 11:51

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million	07:53am	RE
Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill	07-14	CI
Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally	07-14	RE
Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention	07-14	MT
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	07-11	RE
Global markets live: Tesla, Nvidia, Google, BP, Nissan…	07-11
MERCK : Jefferies raises TP after Verona acquisition	07-11
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
Wall Street Waits to Hear the Numbers	07-11
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating	07-11	MT
Merck: Jefferies raises TP after Verona acquisition	07-11
Merck: FDA approval for Bravecto Quantum	07-11
Merck: seeks FDA approval for new HIV treatment	07-11
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S.	07-10	DJ
Merck Animal Health Gets FDA Approval for Bravecto Quantum	07-10	MT
Fda approves Bravecto Quantum, a long-acting injectable for dogs 6 months and older	07-10	RE
Morgan Stanley Adjusts Price Target on Merck to $98 From $99, Maintains Equalweight Rating	07-10	MT
Global markets live: Nvidia, Tesla, Blackstone, BMW, Samsung…	07-10
AI Mania Masks Trade War Risks	07-10
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection	07-10	CI
Merck Says FDA Accepts for Review New Drug Application for Doravirine/Islatravir to Treat HIV-1 Infection in Adults	07-10	MT
Merck : FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection	07-10	DJ
U.S. FDA accepts new drug application for Merck's doravirine/islatravir	07-10	RE
Deals of the day-Mergers and acquisitions	07-10	RE
Formycon tops SDax with news on FYB206	07-10	DP

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

04:45am - International AIDS Society Conference

More about the company